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Introduction 
Cells are constantly exposed to various stresses that damage their DNA, either through 
endogenous sources such as reactive oxygen species (ROS) that form as byproducts of cellular 
metabolism, or exogenous sources such as UV light from the sun, radioactive isotopes, or various 
chemicals in the environment. This damage has to be repaired efficiently and correctly in order to 
maintain cell viability and avoid genomic instability and malignant transformation. To overcome 
the massive task of maintaining the integrity of the genome in such a hostile environment, cells 
have developed a series of mechanisms for DNA damage repair, delay of cell cycle progression, and 
induction of controlled cell death should repair fail, collectively termed the DNA damage response 
(DDR)[1-3]. In the process towards malignant transformation, cancer cells often lose the function of 
one or more regulators of the DDR, and mutations in genes encoding DDR proteins are found in 
several cancer predisposition syndromes. In addition, the microenvironment found in solid tumors 
often differs considerably from that of normal tissues, and these differences may also have a 
profound effect on the regulation of the DDR in cancer cells.  
While failure to repair damaged DNA may lead to cancer, DNA damage is also used to cure cancer, 
and in this regard the DDR insufficiencies of cancer cells may be exploited to improve the 
therapeutic ratio of cancer treatments. However, cancer is not a homogenous disease, and finding 
what subgroups of tumors will respond best to certain treatments requires extensive knowledge of 
the molecular mechanisms involved in mediating treatment efficacy.  
The potential for targeting cancer specific traits by inhibition of the DDR protein Checkpoint kinase 
1 (Chk1) has been the main focus of this thesis. This introduction aims to give an overview of the 
DDR in response to ionizing radiation (IR), the role of Chk1 in both the DDR and normal cell cycle 
progression, as well as the role of tumor hypoxia in modulating the DDR and the efficacy of Chk1 
inhibition.  
 
The ionizing radiation-induced DNA damage response 
DNA damage induced by IR 
Current cancer treatments include three main groups of therapy: Surgery, chemotherapy and 
radiation therapy. Most patients are treated with a combination of these treatments, depending 
on the type of cancer, localization and size of the primary tumor, metastatic spread and other 
factors. As the name implies, IR is photons or particles that have the ability to eject electrons from 
molecules. The resulting ionizations may either occur directly in critical targets or generate free 
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radicals which can interact with other molecules such as water or molecular oxygen, creating more 
stable radicals that can diffuse far enough to reach and ionize critical targets [4]. In cells, the 
majority of the biological damage from X-ray or γ-ray radiation is caused by such secondary free 
radicals [5]. While all molecules in the cell may become damaged in a randomly distributed 
manner, most of these molecules, such as proteins and mRNA, are present in multiple copies and 
have a rapid turnover, thus limiting the consequence of IR-induced damage to them. In contrast, 
DNA is only present in two copies, has a very low turnover if any, is vital for all cellular functions 
and constitutes the largest target [4, 6]. IR causes several types of damage to the DNA, including 
single-strand breaks (SSBs), damaged bases, double-strand breaks (DSBs) and DNA-DNA and DNA-
protein crosslinks [5, 7]. A dose of 1Gy is estimated to result in ~105 ionizations, >103 damaged 
bases, approximately 103 SSBs and 20-40 DSBs [5], but will only result in death of about 30 percent 
of the cell population for a typical mammalian cell line due to the activity of efficient repair 
pathways. Of these insults, DSBs are considered the most lethal[8], even though they are far 
outnumbered by the other forms of damage. DSBs are repaired through two main mechanisms: 
Non-homologous end-joining (NHEJ) and homologous recombination repair (HR). These 
mechanisms will be further described in a later section. SSBs and damaged based are repaired via 
the closely related SSB repair and base-excision repair pathways, respectively, while crosslink 
repair is dependent on the Fanconi anemia (FA) pathway. Cells also have specialized mechanisms 
for repair of mismatched bases (mismatch repair (MMR)) and bulky lesions (nucleotide excision 
repair (NER)), which typically occur during replication and in response to UV-light, respectively. 
However, these repair mechanisms are less relevant for IR-induced damage[9].          
DNA damage sensors 
The first step in activation of the DDR following IR-induced DNA damage is the sensing of the 
damage and recruitment of proteins that control repair, checkpoint and cell death pathways. Three 
kinases of the PIKK (phospho-inositide3-kinase related kinases) family play fundamental roles in 
this process[1]. ATM (Ataxia telangiectasia mutated) is the main kinase in response to DSBs, while 
DNA-PK (DNA-dependent protein kinase) responds to sensors involved in the NHEJ pathway. ATR 
(ATM-and Rad3 related) is recruited to sites with stretches of single-stranded DNA (ssDNA), which 
includes stalled replication forks and resected SSBs and DSBs. All three of these kinases are able to 
phosphorylate the C-terminal Ser139 on the histone variant H2AX (known as γH2AX)[10], one of 
the first steps in forming IR-induced foci (IRIF), microscopically visible regions of accumulated DDR 
proteins [11].  
   
 3 
 
MRN and ATM 
DSBs are initially recognized by the MRN complex, which includes the Mre11 nuclease, DNA 
binding protein Rad50 and ATM-interacting Nbs1 (Nijmegen breakage syndrome 1) (reviewed in 
[12-14]). Binding of ATM to Nbs1 activates ATM [15], which then phosphorylates itself [16, 17], 
MRN and several other downstream targets including H2AX. This creates a docking site for the 
recruitment of the mediator protein MDC1 (mediator of DNA damage checkpoint protein 1) which 
binds γH2AX via its BRCT-domain [18]. MDC1 also binds ATM, leading to further recruitment of 
ATM to the damage site, initiating a positive feedback loop of protein accumulation and 
amplification of the DNA damage signal [19]. MDC1 is essential for the recruitment of the repair 
proteins 53BP1 and BRCA1 to the sites of damage via its interaction with the E3 ligase RNF8 
(reviewed in [11]). MDC1 is also required for retention of Nbs1 at sites of DNA breaks [20, 21], 
which is important for maintaining the DDR signaling until repair is complete. Activation of ATM is 
also dependent on acetylation of Lys3016 by the acetyl-transferase Tip60[22, 23], which is 
recruited to DSBs by direct interaction with the MRN complex [24].  
Ku and DNA-PKcs 
The Ku complex, composed of the subunits Ku70 and Ku80,  competes with the MRN complex for 
binding to DNA ends and functions as a DSB sensor (reviewed in[25]). Ku recruits DNA-PKcs to the 
DSB, forming the active kinase complex referred to as DNA-PK, and this constitutes the first step in 
the process of NHEJ (reviewed in [26]). While Ku and DNA-PKcs are fundamental for this repair 
pathway, they do not play a major role in IRIF formation and phosphorylation of H2AX[25].      
ATRIP and ATR 
ATR is not recruited directly by MRN to DSBs, but binds stretches of RPA-coated ssDNA that 
accumulate at resected breaks via its interaction partner ATRIP (ATR-interacting protein)[27]. MRN 
and ATM are required for the initiation of DSB resection, mediated by Mre11 and CtIP[28], but ATR 
eventually replaces ATM at the resected break as ATM loses its affinity for the resected DNA 
strand, resulting in a switch from ATM to ATR mediated signaling[29]. Activation of ATR is 
additionally dependent on the recruitment of the Rad9-Hus1-Rad1 (9-1-1) complex and TopBP1[30, 
31]. The 9-1-1 complex is a trimeric ring-shaped clamp protein that resembles the PCNA 
(proliferating cell nuclear antigen) clamp involved in replication, and encircles the DNA at the 
damage site (reviewed in [32]). Loading of 9-1-1 onto DNA is facilitated by Rad17 in cooperation 
with four subunits of the replication factor C protein (RFC)[33]. TopBP1 binds both Rad9 and ATR-
ATRIP, elevating the kinase activity of ATR[34, 35]. At stalled replication forks TOPBP1 can also 
interact with MDC1 [36], which may further regulate ATR activity. In addition, it was recently 
identified that RHINO (Rad9, Rad1 and Hus1 interacting nuclear orphan) binds both 9-1-1 and 
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TopBP1 at sites of DNA damage and is important for activation of ATR-mediated HR and checkpoint 
signaling, but the exact mechanism is not known [37].  
Cell cycle checkpoints 
The two main DNA damage induced cell cycle checkpoints in mammalian cells are the G1/S and 
G2/M checkpoints, which halt progression of the cell cycle before entry into S phase and mitosis, 
respectively. In addition, mammalian cells exposed to DNA damage also show a delay in S phase 
progression, known as the S phase checkpoint. The main regulators of these DNA damage 
checkpoints are the ATR and ATM kinases in cooperation with the checkpoint kinases Chk1 and 
Chk2. As these kinases arrest cell cycle progression primarily by activating pathways that target the 
activity of cyclin-dependent kinases (CDKs) (Figure 1), I will first briefly review the function of CDKs 
in normal cell cycle progression.   
 
Basic regulation of cell cycle progression by CDKs 
The CDKs are a family of related Ser/Thr kinases, and as the name implies, their activity is 
dependent on their interaction with cyclins, whose expression is restricted to distinct phases of the 
cell cycle (see[38] for a comprehensive overview of cell cycle regulation by CDKs) (Figure 2). In early 
G1 Cdk4 and Cdk6 are the active CDKs forming complexes with the D-type cyclins (D1, D2 or D3). 
Figure 1. Activation of DNA damage-
induced cell cycle checkpoints. In response 
to DSBs, ATM is activated. Active ATM 
phosphorylates the checkpoint kinases Chk1 
and Chk2, leading to inhibition of the Cdc25 
phosphatases. Cdc25 will then no longer be 
able to remove the inhibitory 
phosphorylation on the Cdk-cyclin 
complexes, and CDK activity decreases. ATM 
and Chk2 also promote activation of p53, 
leading to transcriptional upregulation of 
the CDK inhibitor p21. Checkpoint activation 
is also promoted by ATR in response to 
resected DSBs, leading to activation of Chk1 
and decreased Cdc25 activity. Decreased 
CDK activity leads to cell cycle arrest by 
inhibiting replication initiation and mitotic 
entry. See main text for details and 
references.  
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The Cdk4/6-cyclin D complexes phosphorylate the Retinoblastoma protein (pRb), abrogating its 
inhibitory interaction with the transcription factor E2F. Active E2F induces the expression of several 
S phase proteins, including cyclin E which binds to Cdk2, initiating a positive feedback loop of 
increasing CDK activity, phosphorylation of pRb and E2F activity. The inactivation of pRb occurs 
several hours before cells enter S-phase, but marks the restriction point at which the cells are 
committed to start a new cell cycle (reviewed in [39]). 
 
Figure 2. Overview of CDK complexes promoting cell cycle progression. R marks the restriction point where cells are 
committed to initiate a new round of cell division. G2/M marks the transition from interphase to mitosis, another point of 
no return.   
As cells progress from G1 into S phase, cyclin E is degraded and Cdk2 interacts more with cyclin A, 
which later in S phase also interacts with Cdk1 (Cdc2). In G2, the level of B-type cyclins (mainly B1) 
increase and the Cdk1-cyclin B1 complex promotes mitotic entry. In addition, the Cdk1-cyclin A 
complex can also contribute to drive G2 cells into mitosis [40].  In mitosis, the S and M phase 
cyclins are degraded by the anaphase-promoting complex or cyclosome (APC/C), thus efficiently 
turning off the activity of the CDKs. The APC/C is a multisubunit ubiquitin-protein ligase, and its 
activity is dependent on activator subunits, Cdc20 in early mitosis and Cdh1 in late mitosis and 
early G1 (reviewed in [41]).  
In addition to cyclin binding, CDK activity is regulated by binding of CDK inhibitors such as p16, p21 
and p27 and phosphorylation and dephosphorylation events. Phosphorylations that promote CDK 
activity are carried out by the CDK-activating kinase (CAK) [42] and include Thr161 in Cdk1 and 
Thr160 in Cdk2. Phosphorylations that inhibit Cdk1 and Cdk2 activities include Tyr15 and to some 
extent Thr14 residues and are carried out by the Wee1 and Myt1 kinases. These inhibitory 
phosphorylations are removed by the activity of the Cdc25 phosphatases (Cdc25A, Cdc25B and 
Cdc25C)[43]. Cdc25A was first thought to primarily activate the Cdk2-cyclin E and Cdk2-cyclin A 
complexes at the G1/S transition[44], but later studies have shown that it also activates the Cdk1-
cyclin B1 complex at the G2/M transition[45, 46]. Cdc25B and Cdc25C mainly regulate the activity 
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of the Cdk1-cyclin B1 complex in G2 and M [47], though they have also been implicated in the 
regulation of S phase entry [48, 49]. Even so, Cdc25B and Cdc25C have been shown to be 
dispensable for normal cell cycle progression and checkpoint responses in mice [50]. Knockout of 
Cdc25A results in embryonic lethality, while Cdc25B and Cdc25C may compensate for lack of 
Cdc25A in adult tissues [51]. These results indicate that there is considerable redundancy between 
the family members. 
G1 checkpoint 
Activation of the G1 checkpoint is mainly mediated by the ATM-Chk2-Cdc25A and ATM-p53-p21 
pathways (reviewed in [52]), and is reported to be independent of ATR and Chk1 [53], though 
Chk1-mediated signaling for the targeting of Cdc25A may be involved in late G1 [54]. The response 
targeting Cdc25A is a fast and transient process, while the p53-p21 mediated pathway is a slow and 
potentially permanent arrest that involves transcriptional upregulation of the CDK inhibitor p21. 
Activated ATM at sites of DNA damage recruits and activates Chk2, mainly by phosphorylation of 
the Thr68 residue of Chk2 [55]. Activated Chk2 phosphorylates Cdc25A[56], marking this 
phosphatase for degradation, and with Cdc25A no longer available to remove the inhibitory Tyr15 
and Thr14 phosphorylations on Cdk2, CDK activity is decreased. However, this only results in a 
reduced rate of S phase entry within the first 4-6 hours after genomic insult (such as IR-treatment), 
while a full arrest can be observed in G1 phase at later time-points [52]. This later arrest is 
dependent on p53 and p21, and is often lacking in cancer cell lines. ATM and Chk2 both 
phosphorylate p53 [57-59] and its negative regulator Mdm2 [60, 61], resulting in accumulation and 
activation of p53. Active p53 transcriptionally upregulates p21, which binds to and inactivates 
Cdk2-cyclin E and Cdk4/6-cyclin D complexes [62], thus preventing progression into S phase. 
Inhibition of the CDK complexes in early G1 prevents initiation of the positive feedback loop of pRb 
phosphorylation and release of the E2F transcription factors, keeping the cells from passing the 
restriction point and enabling the option of permanent G1 arrest [52].  
S phase checkpoint 
As is the case in late G1, activation of the intra-S phase checkpoint after IR can only delay cell cycle 
progression, but not induce permanent arrest. This delay in S phase progression is mediated by the 
same mechanisms as the immediate G1 checkpoint, the inhibition of CDK activity by targeting of 
Cdc25A for degradation via phosphorylation by Chk1 and Chk2 downstream of ATM and ATR [63]. 
IR-induced decreased CDK activity prevents the firing of new replication origins [64, 65] and slows 
down replication fork progression [66](see also section on Chk1 and regulation of CDK activity), 
thus delaying the rate of replication and extending the time spent in S phase. In addition to the 
initial IR-induced DSBs, the progression of the replication forks can induce secondary DNA damage 
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that may contribute to the activation of ATR and Chk1 mediated signaling and repair pathways 
[67].  
G2 checkpoint 
Cells irradiated in G2 activate an immediate and transient arrest before mitotic entry by targeting 
the interaction between Cdk1 and the mitotic cyclin B1 via the ATM-Chk1-Cdc25 pathway, similar 
to what is observed in the other cell cycle phases. Chk2 does not appear to play a role in G2 
checkpoint regulation, though studies on this subject have been conflicting (reviewed in [68, 69]). 
Cells that were irradiated in S phase will also accumulate in late G2 until repair is completed, as the 
S phase checkpoint can only delay, but not arrest cell cycle progression, as described above. 
However, this late arrest is independent of ATM, depending instead on ATR-Chk1 signaling and may 
last for many hours after higher doses of IR [70]. The dependence of the G2 accumulation on ATR-
Chk1 may reflect the type of damage that remains at these later time-points [67]. Repair by NHEJ is 
a rather quick process, and breaks that are not efficiently repaired by this mechanism are further 
resected to promote HR, which is a slow process that may take several hours to complete [71]. 
Indeed, several factors involved in HR have also been shown to be important for activation and/or 
maintenance of the late G2 checkpoint, including BRCA1, BRCA2 and its interaction partner PALB2 
[37, 72, 73]. This repair pathway is described in the next section. The role of p53 and p21 in G2 
arrest has been unclear in previous studies (reviewed in [52]), but a recent study found that both 
Chk1 and p21 are required for sustained G2 arrest in cancer cell lines while Chk1 may be 
dispensable when the ATM/p53/p21 pathway is fully functional [74]. Mitotic entry after induction 
of G2 checkpoint arrest requires the cessation of checkpoint signaling and the reactivation of the 
Cdk1-cyclin B1 complex (reviewed in [75]). This process is dependent on the kinase Plk1 (Polo-like 
kinase 1), which targets both Wee1 and the Chk1 regulator Claspin (described below) for 
proteasomal degradation [76-79]. Activation of Plk1 is dependent on the Bora-Aurora A kinase 
complex [80], which also regulates unperturbed mitotic progression [81]. In addition to Plk1, 
checkpoint recovery is also dependent on the activity of several phosphatases that remove the 
activating phosphorylations on Chk1 and other checkpoint proteins (reviewed in [82]). These 
phosphatases include PP2A (protein phosphatase 2A)[83] and Wip1 (wild-type p53-induced 
phosphatase 1)[84, 85].          
DNA double-strand break repair 
As previously mentioned, mammalian cells have two main pathways for repair of DSBs: The “quick 
and dirty” option of NHEJ and the slow but error-free HR (Figure 3). While NHEJ can take place in 
all phases of the cell cycle, HR is mainly restricted to S and G2 phases, where a sister chromatid is 
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available. Both repair pathways are initiated by binding of the MRN complex and activation of ATM, 
but different protein complexes are involved in the subsequent steps of repair. 
 
Figure 3. Simplified overview of the NHEJ and HR repair pathways. DSBs are initially recognized by the MRN complex. 
Replacement of the MRN complex by the Ku70/Ku80 dimer promotes recruitment of DNA-PKcs and repair by the NHEJ 
pathway. The nuclease Artemis initiates simple end processing, and a ligase complex including XLF and Ligase IV mediates 
end ligation of the processed ends, resulting in repair of the DSB with minimal resection taking place. In S and G2 phases, 
where CDK activity is high, end resection of the DSB is initiated by CtIP, followed by further resection mediated by 
Exo1/Dna2. RPA binds the resulting stretches of ssDNA. RPA is replaced by Rad51, whose loading is facilitated by BRCA2. 
Rad51 filaments in association with other HR factors then initiates homology search and strand invasion at the sister 
chromatid, using this as a template for new stretches of DNA, resulting in error-free repair of the DSB. See main text for 
references.      
 
Homologous recombination repair 
HR is dependent on 5’ to 3’ resection of the DSB, which is initiated by the Mre11 nuclease in 
cooperation with CtIP [28]. The association of CtIP to the MRN complex is dependent on BRCA1 
[86]. Further resection is carried out by the exonuclease Exo1 or nuclease Dna2 in cooperation with 
the helicase BLM [87], resulting in long stretches of ssDNA that are immediately coated by RPA. 
RPA is then replaced by the recombinase Rad51, whose recruitment to DSBs is dependent on 
BRCA2 and its interaction partner PALB2 (reviewed in [88]), creating a nucleoprotein filament that 
initiates homology search, strand invasion and DNA synthesis by an unknown polymerase using the 
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sister chromatid of the damaged stretch as a template [89], resulting in error-free repair of the 
damaged DNA. 
Non-homologous end-joining 
NHEJ is initiated by the binding of the Ku complex to the break ends, which replaces the MRN 
complex and thus removes ATM from the break site (reviewed in [90]). As previously mentioned, 
the Ku complex is a heterodimer composed of the Ku70 and Ku80 proteins, and their binding to 
DSBs recruits DNA-PKcs to the DSB. Binding and activation of DNA-PKcs leads to recruitment and 
activation of the nuclease Artemis, in addition to the other necessary repair proteins, which include 
the μ and λ polymerases and a ligase complex (XLF with DNA ligase IV), resulting in an efficient 
ligation of the DNA strands with minimal resection taking place (reviewed in [26]).  
Choice between HR and NHEJ 
The shift between NHEJ and HR mediated repair is primarily mediated by the initial resection taking 
place at the DSB, which also shifts the DDR response from ATM to ATR mediated signaling. The 
resection is regulated by CDKs, which phosphorylate CtIP in addition to several other factors 
involved in both initial DSB sensing and HR repair (reviewed in [91, 92]). CtIP activity is dependent 
on phosphorylation on Thr847 [93], while its interaction with BRCA1 and thus recruitment to sites 
of damage depends on phosphorylation on Ser327 [86]. BRCA1 is also regulated by CDKs, being 
phosphorylated on Ser1497 by Cdk2 [94] and at Ser1497 and Ser1189/Ser1191 by Cdk1 [95]. These 
phosphorylations are likely to be important for Rad51 recruitment [91]. CDKs have also been 
reported to phosphorylate Mre11 [96], Nbs1 [97] and BRCA2 [98], regulating their activity and/or 
interactions with other proteins. Confinement of HR to S and G2 phases thus appears to be largely 
regulated by CDK activity, and is yet another example of the extensive crosstalk taking place 
between the DDR and cell cycle machinery.  
While CDK activity and regulation of resection may restrict the use of HR to S and G2, NHEJ is used 
throughout the cell cycle and is the major pathway for repair of direct two-ended DSBs also in S 
and G2 phase [99]. HR appears to be favored in the repair of more complex and persisting two-
ended DSB (reviewed in [100]), in particular for DSBs in heterochromatic regions [101, 102], and is 
also required for repair of one-ended DSBs formed by collapsed replication forks [103, 104]. 
Interestingly, a recent study showed that loss of NHEJ proteins increases resection, suggesting that 
ongoing NHEJ suppresses HR repair [71].  
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Cell death after IR 
When cells are unable to sufficiently repair the damage induced by IR, they can lose their ability to 
proliferate or undergo cell death through various pathways. How, when and why cells die after IR 
varies between different cell types, with some being more prone to apoptosis while others hardly 
ever die by this mechanism[105]. The timing and mechanism of IR-induced cell death may even be 
different for individual cells within a homogenous population. For cells that undergo a few cell 
divisions after being irradiated, each of the daughter cells may die in different ways and at different 
times[106, 107]. Nevertheless, the susceptibility to certain modes of cell death can be an important 
factor in determining the radiation sensitivity of tissues. Cancer cells often display mutations in 
these pathways, and may therefore respond differently to IR than the normal tissue from which 
they originated.   
Apoptosis 
Apoptosis is a tightly controlled mode of cell death that is an essential part of embryonic 
development, tissue homeostasis, immune system regulation and several other normal 
physiological processes (reviewed in [108-110]). It may be activated via an extrinsic pathway 
regulated by the binding of extracellular ligands to death receptors or an intrinsic pathway 
dependent on intracellular signaling, such as in the response to DNA damage. Both pathways are 
initiated by caspases, a family of cysteine proteases which under normal conditions are kept in an 
inactive form known as procaspases[111]. The intrinsic pathway is initiated by caspase 9, whose 
activation is primarily regulated by the balance of pro- and anti-apoptotic proteins [112]. These 
proteins include the anti-apoptotic BCL2 and pro-apoptotic BAX and PUMA, the latter two being 
induced by p53 activation. These proteins reside in or near the mitochondria and a shift in favor of 
pro-apoptotic proteins results in the release of cytochrome c and other mitochondrial proteins into 
the cytoplasm, triggering the formation of a structure known as the apoptosome and subsequent 
activation of caspase 9. Caspase 9 initiates a signaling cascade of caspase activation, resulting in the 
cleavage of a large set of cellular proteins by effector caspases (including caspase 3) leading to cell 
death. Cells that die via apoptosis display a distinct morphology that includes membrane blebbing, 
DNA fragmentation, chromatin condensation and packaging of cellular components into 
membrane-enclosed apoptotic bodies that in vivo are taken up and digested by phagocytes. This 
highly ordered mode of cell death and breakdown of components prevents inflammation and 
damage to the surrounding tissue, unlike what is observed when cells burst and die via necrosis.  
Autophagy 
Autophagy literally means “self-eating”, and is primarily a mechanism for survival in stressful 
conditions such as growth factor deprivation, starvation or hypoxia, though extensive autophagy 
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does lead to cell death [113]. This involves the digestion of mitochondria and other larger cellular 
structures. Autophagy is characterized by some of the same morphological changes observed in 
apoptotic cells, including membrane blebbing and chromatin condensation, but no DNA 
fragmentation.  
Necrosis 
Necrosis is characterized by cell swelling, breakdown of the extracellular membrane, non-
condensed chromatin and generally a disorganized cellular structure. This is considered to be an 
“accidental” and uncontrolled form of cell death, which typically occurs in response to extreme 
conditions of extracellular pH changes, ion imbalance or energy loss, but also in response to IR-
induced DNA damage. Necrosis is also phenotypically similar to the regulated process of 
necroptosis, and may itself be a more regulated process than initially assumed (reviewed in [114]). 
Senescence 
When cells permanently lose their ability to divide, either due to shortening of telomeres or in 
response to irreparable DNA damage, they enter a state of cell cycle arrest termed senescence 
(reviewed in [115]). These cells display a distinct morphological phenotype that includes a flattened 
cytoplasm, high granularity and often enlarged size. They also have increased expression of β-
galactosidase, which is commonly used as a biochemical marker to detect senescent cells, and may 
have increased regions of heterochromatin. Induction of senescence in response to DNA damage 
appears to be mainly regulated by the p53/p21 and pRb/p16 pathways.  
Mitotic catastrophe (mitosis-linked death) 
Cancer cells often have mutations in genes involved in the regulation of apoptosis and senescence 
(such as p53, which is involved in both), and may survive massive amounts of unrepaired DNA 
damage provided they do not attempt cell division. Mitotic catastrophe, or mitosis-linked death, is 
a term that refers to cell death that occurs as a result of or following aberrant mitosis, and is 
frequently observed in irradiated cells (reviewed in [116]). Cells that undergo mitotic catastrophe 
typically display multiple nuclei, uncondensed chromatin, micronuclei/nuclear fragments and 
chromosomal aberrations. These cells may later die via any of the other cell death mechanisms 
(apoptosis, necrosis, senescence or autophagy), but this death occurs as a consequence of cells 
undergoing mitosis in the presence of unrepaired or misrepaired DNA damage, and is not directly 
triggered by the initial damage.  
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Checkpoint kinase 1 
While Chk1 is a key regulator of the IR-induced S and G2 checkpoints, as described above, it also 
plays a role in normal cell cycle progression. Chk1 null mice die early in embryogenesis, while mice 
with heterozygous knockout of Chk1 are reported to be overtly normal [117-119]. However, 
conditional knockout of one allele of Chk1 in adult mouse mammary epithelial tissue resulted in 
activation of an extensive DDR, showing Chk1 to be haploinsufficient for normal growth in such 
tissues [120]. Abrogation of Chk1 function by inhibitors or knockdown by interfering RNA (shRNA or 
siRNA) in mammalian cell cultures results in increased replication initiation followed by replication 
stalling and DNA breakage [121], in addition to premature mitotic entry [122] and aberrant mitosis 
[123]. These results show that Chk1 is not only required for checkpoint responses following DNA 
damage, but also for maintenance of genomic integrity via multiple functions in the unperturbed 
cell cycle. This chapter will present some of the functions of Chk1 in these vital processes, both in 
unperturbed and damaged cells, and how these functions may be targeted to improve cancer 
therapy.         
Activation of Chk1 
As previously mentioned in the chapter regarding DNA damage induced cell cycle checkpoints, 
Chk1 is activated by ATR (and to some extent ATM) at sites of RPA-coated ssDNA (reviewed in [124] 
and [125]). ATR phosphorylates Chk1 on Ser317 and Ser345 [117, 126-128], which is assumed to 
alleviate inhibitory intramolecular interactions between the N-terminal kinase domain and 
regulatory C-terminal domain of Chk1, allowing Chk1 to assume an active conformation and 
phosphorylate itself at Ser296 [129]. However, it is unclear whether the C-terminal domain of Chk1 
actually binds the N-terminal domain [124, 128, 130, 131], and Chk1 has been shown to be in an 
open conformation also in its inactive and non-phosphorylated state [130]. Recently, an alternative 
splice variant of Chk1, Chk1-S, was shown to function as an endogenous inhibitor of Chk1 [132], 
consistent with the model of a repression factor binding the C-terminal domain to regulate Chk1 
activity rather than this domain folding back on the N-terminal kinase domain [128]. Following 
phosphorylation of Ser296, the Ser317 and Ser345 residues are dephoshorylated by phosphatases 
including PP2A [133, 134] and Wip1 [85], facilitating release of Chk1 from chromatin and spreading 
to the nucleoplasm, where it can interact with its targets such as Cdc25A. Phosphorylated Ser296 
on Chk1 acts as a binding motif for 14-3-3γ, which promotes nuclear retention of Chk1 and 
mediates the interaction between Chk1 and Cdc25A [135]. The C-terminal regulatory domain of 
Chk1 is also phosphorylated by other kinases than ATR. Ser286 and Ser301 are phosphorylated by 
CDKs in mitosis and in response to replication stress [136, 137], while Ser280 is phosphorylated by 
p90 ribosomal S6 kinase (p90 RSK) in response to growth factor stimulation [138].   
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Chk1-mediated regulation of CDK activity  
While the activity of ATR and Chk1 increases in response to DNA damage, these proteins are also 
active in the normal unperturbed cell cycle, regulating the levels and activity of the Cdc25 
phosphatases, and thus the CDK activity. Most of the detrimental effects observed in response to 
Chk1-inhibition are mediated by deregulated CDK activity [139], and may be alleviated by co-
depletion of Cdc25A [140]. As mentioned in the section on cell cycle checkpoints, Chk1 
phosphorylates Cdc25A, Cdc25B and Cdc25C, preventing these phosphatases from removing the 
inhibitory phosphorylations on Tyr15 and Thr14 on Cdk1 and Cdk2. Chk1-mediated 
phosphorylation of Cdc25A leads to inactivation of Cdc25A via degradation[63, 135]. Chk1 
phosphorylates Cdc25A on Ser76, and also activates the kinase Nek11 (Never in mitosis gene-A 
related kinase 11) which phosphorylates Cdc25A on Ser82, marking it for β-TrCP-SCF dependent 
ubiquitination and proteosomal degradation [141]. In the absence of Chk1, Cdc25A accumulates 
[63], resulting in increased activity of CDK complexes, with subsequent detrimental effects on 
replication and mitosis as discussed below. In contrast to Cdc25A, Cdc25B and Cdc25C are not 
degraded in response to Chk1-mediated phosphorylation, but their inactivation is also dependent 
on interaction with 14-3-3 proteins. Phosphorylated Ser323 on Cdc25B and Ser216 on Cdc25C [142, 
143] form binding motifs recognized by 14-3-3 proteins, which sequester Cdc25C in the cytoplasm 
and prevent Cdc25B from interacting with the Cdk1-cyclin B complex [144]. Chk1 may also regulate 
CDK activity by phosphorylating and activating Wee1 [139, 145], the kinase that puts on the 
inhibitory Tyr15 phosphorylation on Cdk1 and Cdk2.      
Chk1 and DNA replication 
Replication of mammalian genomes is initiated at multiple sites called origins of replication, 
marked by the binding of proteins forming the origin recognition complex (ORC) (reviewed in 
[146]). In late M and early G1 phase ORCs recruit Cdc6 and Cdt1, which are responsible for ATP-
dependent loading of the MCM helicase, a structure composed of MCM2-7 proteins that encircle 
the DNA double-strand and is loaded as bi-directional double hexamers, forming the pre-
replication complex (pre-RC). The MCM complexes are initially inactive as helicases until early S-
phase, when the pre-RCs are phosphorylated by CDK (Cdk2) and Cdc7-Dbf4 (DDK) kinases, 
triggering recruitment of Cdc45 and And1-Ctf4 via Treslin and GEMC1 [147, 148]. And1 in 
association with its interaction partners Tim1 and Tipin is crucial for the recruitment of polymerase 
α and replication initiation [149], while Cdc45 in cooperation with the GINS heterotetrameric 
complex stimulate the activity of the MCM helicase to form a productive replication fork [150]. 
Licensed origins are activated in a highly regulated manner and at different times during S phase 
within replication factories, discrete clusters of chromatin coupled to replication machinery 
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proteins [151]. In the course of a normal S phase, only a small fraction of the licensed origins are 
fired, with the majority of the origins being passively replicated by adjoining replication forks. 
However, in response to replication stress these dormant origins may be fired to compensate for 
lack of replication at stalled forks. Activation of replication factories may be regulated separately 
from origin activation within factories by CDKs [152, 153]. Activated Chk1 suppresses initiation of 
origin firing [154]. Such Chk1-mediated suppression of origins occur particularly in new replication 
clusters, while Chk1 can promote firing of dormant replication origins within ongoing replication 
clusters [155]. This allows for the continued replication of ongoing regions despite decreased total 
rate of DNA synthesis in response to Chk1 activation, as is observed after activation of the S phase 
checkpoint. Inhibition of Chk1 in normal S phase cells, and subsequent elevation of CDK activity due 
to accumulation of Cdc25A, leads to increased Cdc45 loading at replication origins, unscheduled 
initiation and accumulation of ssDNA near replication origins, followed by massive replication 
stalling and formation of DSBs [121](Figure 4). Thus, Chk1 is required during normal S phase 
progression to prevent DNA breakage and maintain genome integrity.  
 
Figure 4. Consequences of Chk1 inhibition in S phase cells. In the unperturbed S phase, Chk1 regulates CDK activity 
through maintenance of Cdc25 levels. CDK activity regulates replication initiation, and in the absence of Chk1 Cdc25 
accumulates, resulting in increased CDK activity. This leads to unscheduled replication initiation followed by replication 
stalling and formation of aberrant fork structures. Such structures are processed by nucleases, whose activity is also 
regulated by CDK activity, resulting in DNA breakage. Figure is adapted from [139].  
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While deregulated CDK activity may be the instigator of the unscheduled replication initiation in 
response to Chk1 inhibition, Chk1 has additional roles in replication and maintenance of genomic 
stability in S phase. Both ATR and Chk1 are directly bound to replication forks via RPA and Claspin 
in a complex with the replisome-associated proteins Tim and Tipin in addition to several other 
factors involved in replication [156], and are required for stabilization of stalled replication forks 
[157, 158]. Stalled replication forks often occur in regions that are difficult to replicate, such as 
common fragile sites [159], but may also be caused by such factors as lack of nucleotides or DNA 
bound protein complexes that hinder the progression of the polymerase [160]. Claspin is required 
for activation of Chk1 by ATR[161, 162], functioning as a bridge between these kinases, and is also 
required for recruitment and phosphorylation of BRCA1[163]. Phosphorylation of Claspin by Casein 
kinase 1 (CK1) promotes its interaction with Chk1 [164], which correspondingly promotes the 
stability of Claspin via a kinase-independent and ATR-independent mechanism [165]. When stalled 
replication forks collapse, they form a DSB that requires the HR pathway for repair. Chk1 directly 
regulates this repair pathway by phosphorylating Rad51 [166], a prerequisite for the activation of 
Rad51 and formation of the filaments that perform homology search and strand invasion. Chk1 
also regulates the replication checkpoint, whose function is to ensure the completion of DNA 
replication before chromosomal condensation and mitotic entry as described below.  
Chk1 and mitosis 
Mitotic entry and progression is orchestrated through several positive and negative feedback loops 
of kinases and phosphatases (reviewed in [167]). The main regulator of this process is the Cdk1-
cyclin B complex, whose activity is dependent on the Cdc25 phosphatases as described above. 
Cdk1-cyclin B activity inhibits the Wee1 and Myt1 kinases, while activating Cdc25 family members, 
forming a positive feedback loop for increasing Cdk1 activity (reviewed in [47]). Chk1 is found at 
the centrosomes in interphase [122], where it is assumed to shield Cdk1 from interacting with 
Cdc25B. In the absence of Chk1, the Cdk1-cyclin B complex is prematurely activated, resulting in 
aberrant mitotic entry and disruption of the replication and spindle assembly checkpoints. Cells 
lacking Chk1 may thus enter mitosis before completion of replication [168], with the concomitant 
risk of chromatid breakage, genomic instability and/or death via mitotic catastrophe. In response 
to exogenous DNA damage, mitotic entry is also prevented via Chk1 mediated phosphorylation of 
Cdc25A[46]. Furthermore, Chk1 targets the activity of the mitotic regulators Plk1 [169] and Aurora-
B [170], influencing both checkpoint recovery and cytokinesis. Indeed, the mitotic function of Chk1 
linked to the phosphorylation of its Ser345 residue has been reported to be the essential function 
of this kinase, whereas the Ser317-dependent replication and DDR functions are non-essential 
[171].   
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Rationale for using Chk1 inhibitors in cancer treatment 
While Chk1 is involved in several aspects of both the DDR and normal cell cycle progression, it was 
initially its fundamental role in the regulation of the DNA damage induced S and G2 checkpoints 
that was the basis for the development of Chk1 inhibitors and their use in clinical trials to 
selectively target cancer cells [172-174]. Most cancer cells lack a functional G1 checkpoint, 
primarily due to mutation or loss of p53 or one or more factors involved in regulation of the p53 
response, though other cell cycle regulators, such as pRb or CDKs, may be to blame. In contrast, 
mutations in Chk1 or ATR are rarely found in human cancers, although Chk1 frameshift mutations 
have been observed in some endometrial, melanoma, colon and stomach cancer with 
microsatellite instability [175-178]. Cancer cells with mutated p53 thus have only one functional 
DNA damage induced cell cycle checkpoint to depend on for survival following exposure to DNA 
damaging agents, and would therefore be expected to be selectively sensitized to DNA damage by 
Figure 5. Rationale for using 
inhibitors of Chk1 to target p53 
deficient cells. In response to 
DNA damage, cells depend on 
the activity of the G1, S and G2 
checkpoints for survival. Chk1 
regulates the S and G2 
checkpoints, whereas the G1 
checkpoint (and to some extent 
G2 checkpoint) is dependent on 
p53. Cancer cells often lack 
functional p53, and will 
therefore only have the S and 
G2 checkpoints to depend on 
for survival in response to DNA 
damage. These cells would 
therefore be expected to be 
selectively sensitized by 
inhibitors of Chk1, as they then 
have no functional checkpoints, 
whereas cells with functional 
p53 will still be able to arrest in 
G1. 
 17 
 
abrogation of Chk1 and subsequent loss of the G2 checkpoint (Figure 5)[179, 180]. Though 
inhibition of Chk1 has been shown to enhance the effect of several DNA damaging agents such as 
IR, gemcitabine, anti-metabolites, cisplatin, topoisomerase I poisons and cisplatin (reviewed in 
[181]), the results regarding the importance of p53-status have been more inconclusive, which led 
us to initiate the study presented in paper I. The role of Chk1 in HR has also been suggested to be 
the main instigator of increased sensitivity to these DNA damaging agent rather than its role in G2 
checkpoint regulation [182], though this may also be a means of selectively targeting rapidly 
dividing cancer cells. Rapidly growing cells will depend more on HR and less on NHEJ than non-
cycling normal cells due to the cell cycle phase dependency of these repair pathways.   
Of the DNA damaging agents tried out in combination with Chk1 inhibitors, the greatest sensitizing 
effects were observed with agents that induce a replication stress response, such as anti-
metabolites and topoisomerase I poisons [180]. While Chk1 is rarely mutated in human cancer, it is 
frequently upregulated and/or activated in cancers with expression of replication stress-inducing 
oncogenes [183], such as Myc and Ras [184, 185]. Chk1 inhibitors have therefore been suggested 
as a means of selectively targeting cancers with high levels of oncogene-induced stress, such as 
melanomas [186] and Myc-driven lymphomas [187]. Activation of an ATR and Chk1-mediated 
replication stress response has also been observed in cells exposed to extreme hypoxia [188], and 
Chk1 inhibitors have therefore been proposed for selective targeting of such cells (see section on 
Hypoxia and activation of the DDR).        
 
Hypoxia 
Angiogenesis and tumor hypoxia 
As a solid tumor forms, it outgrows it nutrient and oxygen supply, and must induce the formation 
of new blood vessels in order to grow further. This transition from a microscopic tumor to a 
macroscopic tumor with its own vascular system is known as the angiogenic switch [189]. 
Angiogenesis, or the formation of new blood vessels, is usually a tightly regulated process that is 
only turned on during distinct physiological processes such as embryogenesis or wound healing, 
and blood vessels in normal tissues have a well-organized and hierarchical structure to maintain an 
even distribution of nutrients and oxygen from the blood to the tissue. In contrast, the 
angiogenesis in solid tumors is a consequence of irregularities in the control of blood vessel 
formation, resulting in an abnormal vasculature that is often leaky and tortuous, with uneven 
distances between the vessels, blind ends and arteriovenous shunts [190]. Hypoxia occurs in 
regions where this disorganized vasculature is unable to transport sufficient amounts of oxygen via 
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red blood cells to meet the demands of the surrounding cancer cells. Depending on the underlying 
cause of the insufficient oxygen supply, tumor hypoxia may be divided into two main subgroups; 
chronic or acute hypoxia (reviewed in [191]). Chronic, or diffusion-limited, hypoxia is generally 
found in regions far from functioning blood vessels and typically last for hours or days. The most 
extreme cases of chronic hypoxia are associated with necrotic regions found in larger tumors, 
where the oxygen levels are so low they are close to anoxia. In contrast, acute hypoxia is typically 
caused by temporary occlusions in blood vessels or changes in red blood cell flux, and only last for 
minutes or a few hours. Acute hypoxia often occurs in cycles of repeated periods of hypoxia and 
subsequent reoxygenation, and is then referred to as intermittent or cycling hypoxia. Hypoxia 
induces resistance to conventional cancer therapies such as radiation therapy and some forms of 
chemotherapy [192], and may promote a more aggressive tumor phenotype through multiple 
mechanisms (Figure 6). Due to this, hypoxia generally correlates with a poor outcome for cancer 
patients.  
 
Figure 6. Cellular responses to hypoxia. Hypoxia promotes a more aggressive tumor type by stimulating processes 
involved in cancer progression and treatment resistance, and affects many aspects of cellular functions.  
 
Cellular adaptation to a hypoxic environment 
As outlined in Figure 6, cellular adaptation to hypoxia is a complex response which affects many 
basic cellular processes [193], including metabolism, translation and transcription, in addition to 
cell cycle progression as described in the next section. Several of these responses are regulated by 
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the hypoxia-inducible transcription factors (HIFs), the unfolded protein response (UPR) and the 
mTOR (mammalian target of rapamycin) pathway.   
HIFs are heterodimeric transcription factors composed of a constitutive β-subunit (ARNT) and an α-
subunit (HIF1-, HIF2- or HIF3-α) (reviewed in [194]). HIF1 is the best studied of these and is 
conserved in all metazoans, and is the main activator of transcriptional responses to hypoxia. HIF1 
activity is tightly regulated by proteasomal degradation of the α-subunit, mediated by its 
interaction with the von Hippel-Lindau complex (vHL). The interaction between vHL and HIF1 is 
dependent on the hydroxylation of HIF1α by oxygen-activated prolylhydroxylases (PHDs). When 
oxygen levels fall, the PHDs are inactivated, HIF1α is no longer hydroxylated and accumulates. This 
leads to activation of hundreds of downstream target genes of HIF1 including factors involved in 
tumor promoting pathways such as glycolysis, angiogenesis, metastasis, stem cell maintenance and 
immune evasion [195]. Among the best studied targets of HIF1 are VEGF (vascular endothelial 
growth factor), CA9 (carbonic anhydrase 9) and EPO (erythropoietin).  
While the HIF family regulates the transcription of genes involved in both tolerating and 
overcoming hypoxia, the UPR and mTOR pathways primarily modulate translational processes in 
response to hypoxic stress, though they also regulate other processes such as autophagy, apoptosis 
and metabolism [196-198]. Protein synthesis is an energy-consuming process, and inhibition of the 
overall rate of mRNA translation is thus an efficient method for energy conservation in hypoxic 
cells. Hypoxia-induced inhibition of the mTOR complex leads to decreased initiation of cap-
dependent translation, while activation of the UPR by hypoxia results in decreased general 
translation initiation due to inhibition of GDP to GTP exchange in the translation initiation factor 
eIF2 after phosphorylation by the kinase PERK (protein kinase RNA-like ER kinase)[199]. Decreased 
translation may help the cells overcome hypoxic stress by conserving energy, but at the same time 
the cells are dependent on the efficient translation of essential genes, including several HIF targets 
that are required for hypoxia tolerance. Maintaining this balance is to a large extent regulated by 
the mTOR pathway, but there is also a high degree of crosstalk between HIF, mTOR and UPR 
signaling to promote hypoxia tolerance and cancer progression (reviewed in [196]).    
Cell cycle progression in hypoxic cells 
In addition to preserving energy by limiting transcription and translation, cells also delay 
progression through the cell cycle in response to hypoxic stress. The cell cycle response to hypoxia 
is highly dependent on both the severity and duration of oxygen deprivation, and may also vary 
considerably between different cell lines. In anoxic conditions, cellular respiration is severely 
impaired [200], and all replication stops instantly [201]. In response to severe hypoxia, cells in late 
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S phase, G2 and M will continue through to G1 and arrest in late G1 phase [201, 202], though a 
hypoxia-induced G2 checkpoint arrest has been reported in HCT116 cells [203]. This arrest in late 
G1 is known as the oxygen-dependent checkpoint, and it is independent of HIF, p53 and Rb status 
[204-206]. While the molecular mechanism for induction of this checkpoint is not entirely 
determined [193], the CDK inhibitors p27 and p21 appear to play an important role in recovery 
from this checkpoint [205]. Cells may also accumulate in late G1 under conditions of moderate 
hypoxia, but in contrast to the oxygen-dependent checkpoint this arrest is dependent on HIF1α 
[207]. Furthermore, cells exposed to prolonged moderate hypoxia downregulate essential cell cycle 
regulators such as cyclin A[208, 209], D[210] and E[211] as well as Cdc25A[212, 213], and 
upregulate CDK inhibitors including p27[214] and p16[215]. This may play a role in limiting the 
progression from G1 phase, also by activating a pRb dependent arrest in mid-G1 [211, 216]. The 
late G1 arrest has also been shown to be dependent on GCN2 and PERK through regulation of p21 
and HIF1α [217]. On the other hand, cells exposed to hypoxia in low-glucose conditions have 
recently been reported to traverse the G1 arrest and rather accumulate in S phase, a process linked 
to downregulation of HIF1α and p27 [218].  
Following reoxygenation after exposure to severe hypoxia, cells arrested at the oxygen-dependent 
checkpoint at the G1/S border can be observed entering S phase in a synchronous wave, while the 
cells arrested in mid-G1 enter S phase with only slightly delayed kinetics as compared to normoxic 
cells[219]. In contrast to cells in G1 or G2, that tolerate hypoxia remarkably well, S phase cells 
struggle when exposed to severe levels of hypoxia, and are prone to hypoxia-induced cell 
death[201]. S phase progression tends to be slow or non-existent in extreme levels of hypoxia, with 
severely decreased replication initiation and elongation [220]. After prolonged exposure to near 
anoxic conditions cells lose their replicative potential and are unable to resume cell cycle 
progression following reoxygenation [221]. The effects on replication initiation and elongation are 
primarily linked to the inactivation of the enzyme ribonucleotide reductase (RNR). RNR is the 
enzyme that reduces ribonucleotides to their deoxyribonucleotide counterparts, thus providing the 
building blocks for both DNA replication and repair [222]. When oxygen levels fall below 
approximately 1000ppm, RNR activity drops as its enzymatic activity is dependent on free oxygen, 
resulting in replication stalling and activation of the DDR including cell cycle checkpoints [223, 224].           
Hypoxia, DNA repair and genomic instability 
While much of the aggressiveness of hypoxic tumors is related to increased metastasis, 
angiogenesis and resistance to therapy, it is also due to hypoxic cells displaying a so-called 
“mutator” phenotype with a high degree of genomic instability [225]. This genomic instability was 
initially primarily attributed to elevated expression of fragile sites due to replication stress and DNA 
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damage induced by increased levels of ROS in connection to hypoxia-reoxygenation cycles [226], 
but more recently the profound impact hypoxia has on the function of several DNA repair 
pathways has also been implicated [227, 228]. The efficacy of MMR, NER and HR are all impaired in 
hypoxic cells due to decreased activity or levels of essential repair factors [227], and recent studies 
have suggested that also NHEJ function is reduced [229-231]. Among the HR factors found to be 
downregulated by prolonged hypoxia are Rad51, Rad52 and BRCA1 [230, 232-237]. Rad51 and 
BRCA1 expression is regulated by promoter binding of transcription factors in the E2F family, and 
under hypoxic conditions a shift from activating E2F1 to repressive E2F4 complexes takes place, 
resulting in decreased levels of transcription[234]. Hypoxia-induced downregulation of Rad52 
expression appears to rather be regulated by microRNAs (miRs), in particular the hypoxia-regulated 
miR-210 [235]. In contrast, the downregulation of the MMR genes MLH1 and MSH2 in hypoxia has 
been connected to decreased levels of the transcription factor c-Myc [238], indicating that there 
are multiple transcriptional and translational mechanisms involved in the regulation of DNA repair 
pathways in response to hypoxia.   
This impaired DNA repair function may sensitize hypoxic cells to exogenous DNA damaging agents 
as well as to the endogenous DNA damage induced by the stressful microenvironment surrounding 
them. For instance, reduced DNA repair capacity may explain much of the observed increase in 
radiation sensitivity of prolonged hypoxic cells compared to acute hypoxic cells[239]. While the 
oxygen effect still provides some protection for them compared to normoxic cells, these cells will 
remain repair deficient for several hours or even days after reoxygenation, making them even more 
sensitive to IR than normoxic cells. This decreased repair capacity thus provides yet another 
mechanism for explaining the success of fractionated radiation therapy [239], where cells that have 
been exposed to prolonged hypoxia may be reoxygenated before the subsequent dose is 
administered [240, 241]. The impaired HR function has also implicated the use of PARP inhibitors 
for selective targeting of hypoxic cells [220, 227], analogous to the increased sensitivity to these 
inhibitors in cells deficient in HR due to mutations in BRCA1/2 [242, 243]. However, in contrast to 
what is observed after prolonged hypoxia, where HR function is impaired, acute hypoxic cells have 
been reported to be more dependent on HR for survival following IR treatment than normoxic cells 
[244]. This may be linked to differences in the type of DNA damage induced by IR under hypoxia 
versus normoxia [245].               
Hypoxia and activation of the DDR  
As mentioned previously, hypoxic cells struggle with progression through S phase, particularly 
when the level of hypoxia is severe. When oxygen levels are close to anoxia, progression through S 
phase is not only delayed but stops entirely, affecting both replication initiation and elongation, 
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and cell death is induced after just a few hours exposure.  Under such conditions, a massive DDR 
primarily dependent on ATR/Chk1 mediated signaling is activated [224, 246], likely due to the 
formation of long stretches of ssDNA formed at stalled replication forks. This replication stress 
response is similar to the response to hydroxyurea or aphidicolin treatment with regard to 
activation of ATR/ATRIP, Rad17 and Nbs1, though it does not result in DSBs as measured by comet 
assays, 53BP1 foci nor formation of ATM foci [247]. Later studies found that ATM is activated by 
such severe levels of hypoxia, but displays a diffuse staining throughout the nucleus rather than 
form foci [248]. Accumulation of p53 was also observed in arrested S phase cells [224, 249], and 
has been implicated in induction of apoptosis in hypoxic regions (reviewed in [250]). While 
exposure to extreme hypoxia has not been found to induce any measurable DNA damage, 
reoxygenation after such treatment causes massive formation of DSBs with subsequent formation 
of ATM foci and phosphorylation of Chk2 [188]. Chk1 activation in hypoxic cells has been 
implicated in maintaining replication fork integrity and cell cycle arrest [251, 252], and consistent 
with this, cells display increased sensitivity to abrogation of Chk1 or ATR when exposed to severe 
hypoxia and subsequent reoxygenation [251, 253]. Chk1 inhibitors have therefore been suggested 
to selectively target hypoxic cells [220, 254], even though the role of Chk1 in moderate hypoxic 
conditions that do not induce replication stalling has not been elucidated, which led us to initiate 
the study in paper II. However, γH2AX has also been observed in response to moderate hypoxia 
(1% O2) in epithelial cells, where it was found to be required for angiogenesis and cell proliferation 
[255]. Evidently, there is a strong connection between the DDR and adaptation to a hypoxic 
environment, though the interplay between these processes is still poorly understood.         
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Aims of study 
In order to achieve a better understanding of the biological functions of Chk1 and how they may be 
targeted to enhance cancer treatment, we initiated three closely related studies with the aim of 
determining the following: 
- The role of p53 status for the effects of Chk1 inhibitors in combination with IR treatment in 
cancer cells (paper I). 
- The effect of Chk1 inhibition in cells during and after prolonged or acute hypoxia, both in 
the presence and absence of IR treatment (paper II).  
- How exposure to prolonged hypoxia may alter IR-induced G2 checkpoint signaling (paper 
III).  
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Summary of papers 
Paper I 
p53-dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death 
after treatment with ionizing radiation and Chk1 inhibitors 
Inhibitors of Chk1 have been proposed to selectively sensitize p53-deficient cancer cells to DNA 
damage inducing agents by abrogating the G2 checkpoint, based on the hypothesis that these cells 
are more dependent on this checkpoint due to loss of a functional G1 checkpoint. While several 
previous studies have been conducted to determine whether this hypothesis holds true, these 
studies have mainly used chemotherapeutic agents rather than IR to induce DNA damage, few have 
used isogenic cell lines and results have varied, with most studies supporting the hypothesis, while 
others did not. To clarify this issue, we performed the study presented in paper I. In this study two 
isogenic cell systems (differing only in p53 status) were used, the osteosarcoma cell line U2OS-
VP16 with Tetracycline-regulated expression of a dominant-negative version of p53 and the colon 
carcinoma cell lines HCT116p53+/+ and HCT116p53-/-. Chk1 function was abrogated by use of the 
inhibitors UCN-01 and Cep-3891, and the responses to combination treatments of Chk1 inhibitors 
and IR were assessed. HCT116p53-/- cells, but not HCT116p53+/+, showed an increased sensitivity to IR 
in the presence of Chk1 inhibitors as measured by clonogenic survival assays, whereas U2OS-VP16 
cells were radiosensitized by Chk1 inhibition independently of p53 status, with no additional effect 
observed in cells expressing dominant-negative p53. However, when measuring cell survival at 
three days after IR and exposure to Chk1 inhibitors, we observed a p53-dependent response in the 
U2OS cells, with increased cell death in cells expressing dominant negative p53. This p53-
dependent response correlated with a p21-dependent G1 arrest in the second cell cycle after IR. 
However, the effects of p53 status on Chk1 inhibitor cytotoxicity within each isogenic cell system 
were minor compared to the difference in intrinsic sensitivity to Chk1 inhibitors between the cell 
lines, with HCT116 cells being very resistant and U2OS cells very sensitive. This would indicate that 
p53 status may not be the key predictor to Chk1 inhibition response. 
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Paper II 
The efficacy of CHK1-inhibitors is not altered by hypoxia, but is enhanced after reoxygenation  
Hypoxia is a hallmark of solid tumors, and correlates with a more aggressive disease with increased 
metastasis and resistance to therapy. In paper II, we investigated the potential of Chk1 inhibitors 
for selective targeting of hypoxic cells both as a monotherapy and in combination with IR. This 
study was based on previous publications showing that severe hypoxia activates a replication stress 
response involving activation of Chk1 and ATR [188, 251], and that cells irradiated under acute 
hypoxic conditions display an increased dependence on HR for survival [244]. During prolonged 
exposure to non-toxic levels of hypoxia, we found no enhanced cytotoxicity of Chk1 inhibitors 
despite activation of Chk1 and other DDR response proteins. In contrast, Chk1 downregulation by 
shRNA, which also kept Chk1 levels low during the initial 24 hours after reoxygenation, showed 
enhanced cytotoxicity. This indicated that cells may display increased dependence on Chk1 after 
reoxygenation. Consistent with this notion, administration of Chk1 inhibitors after reoxygenation 
following prolonged hypoxia resulted in enhanced γH2AX staining in S phase cells and decreased 
clonogenic survival. This increased sensitivity to Chk1 inhibition did not appear to be caused by 
enhanced unscheduled replication initiation, but rather seemed associated with more replication 
stalling as measured by EdU uptake and RPA phosphorylation. Interestingly, the increased 
sensitivity to Chk1 inhibitors was not only observed after exposure to hypoxia levels activating a 
DDR, but also after more moderate hypoxia that did not appear to cause replication stress. 
Inhibition of Chk1 radiosensitized hypoxic and normoxic cells to a similar extent, with a non-
significant tendency for enhanced effect in hypoxic cells pointing to a slightly increased 
dependency on HR repair.  
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Paper III 
Impact of hypoxia on G2 checkpoint signaling  
Chronic hypoxia is known to impair several DNA repair pathways, including HR and MMR, which 
may be a major factor promoting genomic instability in tumors. The DNA damage induced G2 
checkpoint is also a crucial factor in maintaining genomic stability, but how it is affected by 
prolonged hypoxia is not known. This led us to initiate the project presented in paper III. We found 
by microarray analysis that of a panel of 31 G2 checkpoint regulators, several were downregulated 
at the mRNA level by 24 hours exposure to moderate hypoxia, while others were unaltered or even 
slightly upregulated. On the protein level as measured by Western blotting, the general tendency 
was a downregulation of both positive and negative regulators of the checkpoint, in particular in 
response to more severe hypoxia. One notable exception was p21, which was upregulated by 
hypoxia. However, the prolonged exposure to hypoxia also resulted in an accumulation of cells in 
G1, where the expression of many of the G2 checkpoint regulators is at a minimum. To avoid the 
bias of cell cycle effects and accurately measure the protein levels in individual cells in each cell 
cycle phase, we used multiparameter flow cytometry. We found that the levels of cyclin B and Plk1 
were decreased in G2 cells after exposure to prolonged hypoxia compared to the level in normoxic 
G2 cells, while cyclin A levels were unaltered. Consistent with this, the G2 checkpoint was stronger 
in cells irradiated after prolonged hypoxia than in normoxic cells, even though Chk1 signaling and 
response to inhibition of Chk1 appeared unaltered. In conclusion, altered expression of G2 
checkpoint regulators by prolonged hypoxia may result in increased G2 checkpoint activation, and 
this may counteract rather than promote genomic instability. 
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Discussion  
Experimental considerations 
Cell cultures and hypoxia treatment 
The model system used throughout this thesis was cultured mammalian cell lines, primarily human 
cancer cell lines grown adherently in a monolayer. Cell cultures are one of the most frequently 
used model systems for studying biological responses with regard to cancer therapies, and some of 
the main advantages of this system includes the unlimited supply of homogenous material for DNA, 
RNA and/or protein analysis, the potential for long-term storage in liquid nitrogen and the ease of 
manipulation, whether by transfection, irradiation or addition of chemicals to the culture medium. 
However, these cultured cell lines have been passaged for years ex vivo, and have often lost several 
of their original characteristics in the process of adapting to proliferation in a monolayer under 
conditions of high oxygen (the oxygen level in normal room air and thus in humidified incubators is 
about 20-21%, in normal tissue generally 2-9%[256]) and diabetic glucose levels (glucose in DMEM 
medium is 25mM, 2h plasma glucose levels in a healthy person is <7.8mM according to the World 
Health Organization), in the absence of the hierarchical 3D structure and other cell types usually 
found in the tissue from which they were derived. Some of the observed discrepancies between 
preclinical and clinical studies may to a certain extent be explained by these “un-biological” 
conditions and selection for cells that thrive under them. It is therefore important to keep in mind 
that cultured cells may respond to various treatments in a different way than the tissues they were 
derived from. Even so, cultured cell lines are an invaluable tool in cancer research for 
understanding the underlying biological mechanisms in both cancer development and treatment. 
Different cell lines may display very variable phenotypic and genetic characteristics, and respond 
differently to treatments such as hypoxia, Chk1 inhibition and irradiation, which is why we used 
several cell lines originating from various tissues and tumor types for our studies of these 
responses. Primarily the experiments in all three publications presented in this thesis were carried 
out with U2OS and HCT116 cells, but also HeLa, HT29 and BJ fibroblasts were used to ensure the 
general validity of the findings. U2OS is an osteosarcoma cell line originating from a moderately 
differentiated sarcoma of the tibia of a 15 year old girl, isolated in 1964[257]. It is a chromosomally 
highly altered cell line with chromosome counts in the hypertriploid range, and is wildtype for p53 
and pRb[258, 259]. HCT116 is a near diploid cell line originally isolated as one of three 
subpopulations derived from a primary colonic carcinoma [260]. It is frequently used for knockout 
studies due to its suitability for targeted HR [261]. HeLa is an aneuploid cervical cancer cell line, and 
is also the oldest and one of the most well-studied cancer cell lines in use. HeLa cells contain the 
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human papilloma virus, leading to degradation of p53 and pRb through the activity of the viral E6 
and E7 proteins, but otherwise the p53 and pRb pathways are intact [262]. HT29 is a cell line 
derived from a colon adenocarcinoma in 1964, with a hypertriploid chromosome number 
(www.atcc.org). BJ fibroblasts, a non-transformed human cell line derived from foreskin tissue 
(www.atcc.org), was also used for control experiments for publication I, as it in contrast to the 
cancer cell lines does not have any known mutations in pathways involved in the DDR. All the cell 
lines were mycoplasma-tested regularly and genotyped by STR technology to ensure their correct 
identity. 
In publication II and III, the cell cultures were exposed to various levels of hypoxia (0.2% or ~0.03% 
O2) for durations up to 24 hours, for which an InVivO2 200 chamber (Ruskinn) was used. This 
chamber functions like an airtight cell incubator, with regulated temperature and humidity, and 
also allows for handling of the cell cultures with minimal disturbance of the environment. The gas 
was regulated by a mixer with sensors for O2 and CO2 levels, which ensured flushing of the 
chamber with N2 and CO2 when needed to maintain the set level of these gases. To achieve the 
lowest level of hypoxia (~0.03% O2) a mixture of H2/N2 gas was used in combination with the 
installed Palladium catalyst for removal of the remaining traces of free O2. The gas mixer for the 
hypoxia chamber measures the oxygen level in the gas phase at one minute intervals, but the 
oxygen level in the medium of the cells was not determined at any time during our experiments. 
This would have required the use of oxygen probes inside the chamber, for which the necessary 
tubing and connections were not available in our chamber and which if connected could have 
interfered with the stability of the hypoxic environment. For our purposes, we found it adequate to 
depend on the chamber measurements and settings, and rather analyze more in detail the 
biological responses of each of the cell lines with regard to survival and effects on cell cycle 
progression and potential activation of a DDR. In addition, we tried to minimize variability between 
experiments by plating out cells at the same density and in the same volumes, as these factors may 
influence on oxygen availability and consumption, and thus the severity of the hypoxia [263]. In 
contrast to glass dishes, which are typically used for experiments where the exact oxygen level is of 
major importance and/or one desires to reach near anoxic conditions (less than 100 ppm O2), 
plastic dishes bind oxygen and releases it gradually, resulting in delayed kinetics of achieving an 
equilibrium between the hypoxic gas phase and the cell culture medium [264]. Within the 
timeframe of our experiments (up to 24 hours hypoxic exposure) we did not observe decreased cell 
survival or complete cell cycle arrest, indicating that the oxygen level in the cell culture medium 
remained above 100 ppm throughout the hypoxic exposure [265], even with the use of N2/H2 gas 
and a Palladium catalyst to achieve near anoxic conditions. However, with longer exposures the 
 29 
 
available oxygen from the plastic dishes would be consumed, and this would probably result in 
decreased cell survival and complete replication arrest, consistent with what has previously been 
reported for cells treated with near anoxic levels of hypoxia [188, 201, 219, 224, 265], though we 
did not attempt to test this out as the gas consumption for the chamber was very high at the most 
severe hypoxia setting (~0.03% O2).            
To avoid reoxygenation of the cells, all lysates and flow cytometry samples were harvested inside 
the hypoxia chamber with solutions that had been incubated in containers with open lids in the 
chamber throughout the experiment. Even so, the final step in some of the assays had to be done 
in normoxia, such as the fixation of the flow samples with ice-cold ethanol after centrifugation, but 
this was a process of less than two minutes per sample. For lysates analyzed by Western blotting, 
we could not detect any difference in the results for samples harvested in hypoxia or within the 
initial few minutes after reoxygenation, even for the extremely labile HIF1α, though at fifteen 
minutes after reoxygenation this protein was non-detectable. For more stable proteins, such as 
Chk1, Plk1, cyclin B and cyclin A, we did not observe any change in protein levels at such times after 
reoxygenation, though there was a gradual increase observed at 3-6 hours (paper III). Based on 
these observations, for the checkpoint activation studies in paper III we allowed the cells to be 
reoxygenated 15 minutes before irradiation rather than irradiate them immediately after removal 
from the hypoxia chamber, as we considered this short exposure to normoxia unlikely to have a 
major impact on the G2 checkpoint regulation.  In support of this, we also observed a stronger G2 
checkpoint in cells irradiated during prolonged hypoxia (20 hours of 0.2% O2) compared to cells 
irradiated during acute hypoxia (3 hours of 0.2% O2) (unpublished results), though these cells 
displayed a weaker G2 checkpoint compared to normoxic cells due to less DNA damage induced by 
the radiation treatment because of the oxygen effect.    
Abrogation of Chk1 function  
The development of small molecule inhibitors of Chk1 has become a priority for several 
pharmaceutical companies due to their potential clinical applicability, and many patents for such 
compounds have been applied for [266, 267]. These compounds have various chemical properties 
and selectivity for Chk1, but most of them are ATP competitive structures that bind the active site 
[266, 267]. They therefore often inhibit other kinases in addition to Chk1, but with different 
selectivity, which is why it is so important to test multiple Chk1 inhibitors to ensure that the 
observed effects are truly dependent on Chk1 and not the other kinases targeted by the inhibitor. 
In publication I we used the Chk1 inhibitors UCN-01 and Cep-3891, in study II UCN-01 and 
AZD7762. UCN-01 (7-hydroxystaurosporine) was the first Chk1 inhibitor to be discovered[268], and 
also the first to reach clinical trials [269]. Though primarily used as a Chk1 inhibitor [270], it was 
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originally isolated as a PKC (protein kinase C) inhibitor [271, 272] and additionally inhibits PDK1 
(pyruvate dehydrogenase kinase 1) and AMPK (AMP-activated protein kinase) [273]. Cep-3891 
efficiently abrogates Chk1 function (IC50 4nM), but also targets TrkA (IC50 9nM), MLK1 (IC50 42nM) 
and VEGFR2 (IC50 164nM) in vitro [63]. Unlike UCN-01 and AZD7762, it has never been tested in 
clinical trials due to poor stability in vivo, but has been shown to abrogate S and G2 checkpoints 
after IR [274] in addition to causing increased replication initiation and DNA breakage in 
unperturbed cells [121, 154]. AZD7762 is a newer and more specific Chk1 inhibitor, but in addition 
to Chk1 it also targets Chk2 to a similar extent (IC50 5nM and <10 nM, respectively)[275]. 
 While inhibitors are a quick and efficient way of abrogating Chk1 function, they are also unspecific, 
and in some cases result in different responses than those observed with knockdown or knockout 
studies, where the protein is absent rather than inactivated. Knockdown of the protein of interest 
is achieved by the use of interfering RNA (RNAi), either in the form of vector-based short hairpin 
RNA (shRNA) or chemically synthesized small interfering RNA (siRNA). While we used transient 
transfection of siRNA for knockdown of p21 in paper I, and often have used siRNA for knockdown 
of other proteins including Chk1 for many experiments previously with good results [73, 121], a 
U2OS cell line with Tetracycline-inducible expression of Chk1-shRNA was made for the studies in 
paper II. Chk1 knockdown is in itself quite toxic to the cells, so uneven transfection efficiency 
between single cells in a population and between experiments would result in an unfortunate 
selection for cells where Chk1 knockdown was inefficient in clonogenic survival assays. In order to 
minimize such variability, single clones of stably transfected cells were tested for efficient 
knockdown of Chk1 in response to Tetracycline addition. Out of an initial 24 clones, only two were 
further tested for radiation sensitivity and response to hypoxia based on their normal background 
levels of Chk1 in the absence of Tetracycline and efficient knockdown of Chk1 in the presence of 
this drug (Western blotting showed levels of Chk1 to be less than 1/16 of background levels 
following 48 hours of Tetracycline treatment). One of these clones was discarded from further 
experiments due to increased radiation sensitivity also in the absence of Tetracycline when 
compared to parental U2OS, while the B1-clone used for the experiments in paper II did not 
deviate from the parental cell line in any way tested (clonogenic survival responses to both 
radiation and hypoxia, flow cytometry measurements of cell cycle progression and protein levels 
assessed by Western blotting). In addition to the obvious advantages of having a clonal population 
of cells with drug-inducible expression of shRNA, shRNA is generally also more efficient than siRNA 
and may result in less off-target effects [276]. 
Studies of the immediate responses to loss of Chk1, such as the initial burst of replication initiation 
and mitotic entry, require the use of inhibitors of this kinase, as knockdown with RNAi takes several 
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hours or even days to achieve sufficiently low levels of Chk1 protein. However, RNAi is generally 
more specific, even though this method also may result in off-target effects. Ideally, both 
techniques should be applied when possible, as we have done in publication I and II. 
Cell death and survival assays  
In radiation biology, clonogenic survival assays have generally been considered the “gold standard” 
for determination of treatment efficacy, only surpassed by in vivo mouse models [108]. This assay 
measures the fraction of cells that are able to propagate and form new colonies through several 
rounds of cell division, which is thought to best mimic the fraction of cells that would continue to 
proliferate indefinitely in a tumor, and thus remain a threat to the patient. However, treatment 
efficacy may also be measured by assaying the fraction of dead and viable cells at a shorter time-
point following exposure to cytotoxic agents, typically 2-3 days, such as with the Sytox green 
viability assay used in publication I, or with assays measuring apoptosis, such as the TUNEL assay. 
Viability and apoptosis assays are generally quicker and less laborious than the clonogenic survival 
assays to perform, and though there are exceptions, in particular for the apoptotic assays [108], 
they may correlate with observed responses in vivo [277, 278]. However, apoptosis assays are 
primarily only applicable for cell lines that are particularly prone to this mode of cell death, such as 
hematopoietic cells, and were therefore not suitable for our experiments. In publication I, both the 
clonogenic survival assay and the Sytox green (a non-permeable nucleic acid stain that only stains 
cells with a ruptured membrane) viability assay were used to assess the efficacy and p53-
dependence of Chk1 inhibition in combination with IR in U2OS cells, with only the cell viability 
assay showing a p53-dependent effect. Such discrepancies between clonogenic survival assays and 
short-term viability assays have been observed with regard to p53 status and Chk1 inhibition 
previously [279], and may be one of the reasons for some of the contradictory findings published 
on the subject. Since p53 regulates both cell cycle arrest and apoptosis, lack of this tumor 
suppressor may both promote as well as protect from cell death after DNA damage, and as a 
consequence the mechanism and timing of cell death may vary, but the fraction of cells that are 
able to form new colonies does not necessarily do so. The observed second cycle G1 checkpoint in 
p53-competent U2OS cells is likely protecting irradiated cells from death by necrosis or mitotic 
catastrophe, as measured by the viability assay three days after irradiation, but may also be the 
first step towards DNA-damage induced senescence or activation of p53-dependent apoptosis. 
Even so, the mode and kinetics of tumor cell death may be important for the systemic response to 
treatment with regard to inflammation, fibrosis and other late effects, and should be taken into 
account when considering the validity of cell viability and clonogenic survival assays for prediction 
of in vivo responses.      
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Cell cycle progression measurements 
Treatments with hypoxia, Chk1 inhibition and IR all have in common that they affect cell cycle 
progression. To measure the cell cycle distribution and progression, we used multiparameter flow 
cytometry, a technique that allows for the assessment of DNA content and protein 
modifications/levels within individual cells in a large population (typically 10 000 to 100 000 cells 
are measured for each sample) within a few minutes. Flow cytometry can also be used to analyze 
subpopulations within a large cell culture sample by gating for the populations of interest, such as 
mitotic cells or γH2AX positive S phase cells. The use of this technique for protein measurements is 
discussed in the next section. Fluorescent dyes staining DNA were used for determining the 
fraction of cells with 2n (G1 phase), 4n (G2 or M phase) or intermediate DNA content (S phase 
cells). The DNA stains used were primarily Hoechst 33258 and to a lesser extent Cell Cycle 633, 
depending on which other fluorescent dyes they were to be combined with. With the flow 
cytometer we used for our experiments, Hoechst 33258 was preferred as it generally gave DNA 
histograms with narrower peaks and better separation of the distinct cell cycle phases than the Cell 
Cycle 633 stain, but only the latter fluorescent dye could be combined with the EdU staining or the 
barcoding technique (see below). To separate G2 cells and mitotic cells an antibody against the 
phosphorylated Serine 10 residue of histone H3 was used as a mitotic marker [280]. The 
microtubule inhibitor Nocodazole was used to arrest cells in mitosis for up to 24 hours to measure 
the accumulation of cells that had avoided or overcome the G2 checkpoint arrest and also to study 
G1 arrest, both in response to IR and hypoxia. Longer durations of Nocodazole treatment were 
found to result in a marked increase in the sub-G1 fraction, and could therefore not be used to 
assess G2 checkpoint recovery at such late times after IR.  While the fraction of cells in S phase 
could be calculated to some extent by the DNA content, this method does not separate between 
actively replicating and arrested S phase cells, so for that purpose the nucleotide analog EdU was 
added to the medium of the cells. For determining the fraction of actively replicating cells, a short 
(10 minute) pulse of EdU was given, while a one hour pulse of a lower concentration of EdU was 
used for the more accurate quantification of replication rate in the cells (paper II), as this gave 
more consistent values.     
Measurements of protein levels and modifications 
Three different techniques were used in this thesis to study the levels and post-translational 
modifications of proteins: Multiparameter flow cytometry, Western blotting and 
immunofluorescence imaging (IF). While all three methods rely on the use of specific antibodies, 
they each have distinct properties which make them useful for different purposes. Most antibodies 
work well for Western blotting, with the exception of those that only bind the protein in its native 
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conformation, and the gel electrophoresis process separating the proteins by size minimize the 
problem of unspecific binding to other proteins than the one of interest. However, Western 
blotting is not so suited for measurements of protein levels or modifications that only apply to a 
small fraction of the total cell population. This method will not be able to discriminate between 
large variations in a small fraction of the total population and a small variation in the whole 
population, as the observed band is an indication of the mean protein level for a large population 
of cells. Multiparameter flow cytometry is much better suited for studies with large variations 
within the studied cell population, as it measures the signal within single cells, though there are 
issues with the limited number of antibodies available that are compatible with this technique. So 
far we have therefore only tested with flow cytometry a few of the G2 checkpoint regulators found 
to be downregulated by prolonged hypoxia according to the Western blotting and microarray data 
in paper III. In particular the results for cyclin A and cyclin B in this study show the importance of 
taking cell cycle effects into account, as only the latter was found to be downregulated in G2 phase 
in the flow cytometry data, while both appear to be downregulated when assessed by Western 
blotting using whole cell lysates. This issue may be overcome by synchronizing the cells with 
methods such as the mitotic shake-off technique, though this is not easily achieved in studies such 
as ours where cells are treated with prolonged hypoxia, as such cells tend to accumulate in G1 and 
not enter S phase (paper II and III). One could in principle sort cells by FACS (fluorescence-activated 
cell sorting) according to cell cycle phase and then lyse the fractions for Western blotting analysis, 
but this would require very large sample sizes and is far more laborious than the direct analysis 
with flow cytometry. Flow cytometry thus remains an invaluable tool for acquiring data on protein 
levels and modifications within sub-populations of cells. However, this technique is not suited for 
analysis of subcellular localization or foci formation, for which IF has to be used. In general, the 
antibodies that work well with IF also work for flow cytometry, and the two techniques may be 
combined by sorting the cell population of interest onto microscope slides using FACS followed by 
microscopic analysis [281].        
Measurement of hypoxia-mediated changes in mRNA expression 
For the study of mRNA changes in response to prolonged hypoxia, Illumina microarrays covering 
the whole human genome were used. The results acquired with this method may not be as 
reproducible as those one could achieve using real-time PCR (RT-PCR) or Northern blotting with 
multiple probes for each of the genes of interest, as was evident by the variability in the expression 
pattern found for each gene in those cases where multiple probes were available (results not 
shown). For our purpose the whole pattern of variability for the G2 checkpoint regulators was a 
more important issue than the exact regulation on the transcriptional level for each gene, and for 
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this we found the microarray data to be a useful indicator, while we prioritized the quantitation of 
the protein levels of these genes with Western blotting and flow cytometry. The microarray data in 
paper III were originally produced for a different study using the cervical cancer cell lines HeLa, 
SiHa and CaSki [282], while the U2OS cell line was added to the setup for our study. While there 
was some variability in the results obtained with these different cell lines, most of the genes were 
found to be differentially expressed in a similar pattern in response to hypoxia, and as expected 
many of the most upregulated genes were known hypoxia-regulated genes such as CA9 and VEGF. 
 
General discussion 
p53 status and sensitivity to Chk1 inhibition 
The initial rationale for using Chk1 inhibition for selective sensitization of cancer cells to DNA 
damaging agents was based on the theory that cells that lack a functional G1 checkpoint would 
depend more on the S and G2 checkpoints for survival, and abrogation of these latter checkpoints 
would thus selectively target p53-mutant cells. This also remains the rationale for targeting of triple 
negative breast cancer by Chk1 inhibition, as these tumors display a high rate of p53 
mutations[283], though other factors such as oncogene-induced replication stress [185, 187] are 
emerging as other potential genetic markers for increased efficacy of such inhibitors.  
Our study in paper I indicated that there is indeed an enhanced effect of Chk1 inhibition in cells 
lacking p53 compared to their p53 wildtype counterparts, though this study also showed that the 
cytotoxic effects of Chk1 inhibition alone were much greater in the U2OS than the HCT116 cell line, 
irrespective of p53 status. Like all cancer cells, these cell lines harbor various mutations that have 
accumulated through their process towards malignant transformation, and in particular for U2OS it 
is evident that the p53 pathway is not entirely functional. While this cell line does activate 
expression of p21 in response to IR, the response is much slower than what we observed in HCT116 
cells, and this was also evident in the microarray data in paper III, where transcription of CDKN1A 
(p21) was strongly upregulated in HeLa, but not in U2OS after 24 hours treatment with 0.2% O2. 
This delayed expression of p21 is likely the reason for the failure to arrest in G1 in the first cell cycle 
after IR, while the cells have managed to accumulate sufficient p21 in the second cell cycle to 
arrest there, as observed in paper I. It was also interesting to notice the difference between 
HCT116 and U2OS with regard to the radiosensitizing effect of Chk1 inhibition. HCT116p53-/- but not 
HCT116p53+/+ cells were affected, whereas U2OS cells displayed increased radiation sensitivity 
regardless of p53 status, consistent with an aberrant regulation of this pathway. This may be 
caused by mutations in genes encoding proteins involved in the regulation of p53 such as Mdm2. 
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Indeed, U2OS has been found to overexpress Mdm2, but this study found HCT116 to do the same 
[259], and in contrast to U2OS, the HCT116 cell line is able to activate a G1 checkpoint immediately 
after IR (paper I).    
Compared to other cell lines, U2OS cells seem sensitive to inhibition of Chk1, whereas HCT116 cells 
are exceptionally resistant (paper I, paper II and unpublished observations). The resistance of 
HCT116 to the detrimental effects of CHK1 inhibition may be coupled to the mutation in MRE11 
found in this cell line [284]. DNA DSB formation following inhibition of Chk1 has been shown to be 
dependent on the activity of the endonuclease Mus81/Eme1 [285], and Mre11 has been shown to 
be involved in degradation of stalled replication forks [286-288], so it could be that the decreased 
Mre11 function in HCT116 cells prevents excessive DNA resection and DSB formation following 
Chk1 inhibition. Indeed, a recent study showed that Mre11 is critical for the sensitivity of cells to 
Chk1 inhibition [289]. Another factor linked to increased sensitivity to inhibition of Chk1 is high 
levels of replication stress and genomic instability as measured by γH2AX staining in S phase during 
unperturbed cell cycle progression [186], though the correlation was rather inconsistent for the 
various cell lines tested in this study. For U2OS and HCT116 cells we observed far lower levels of S 
phase γH2AX in the prior than the latter cell line (paper II), indicating that in the case of these cell 
lines the correlation is inverse. High levels of cyclin B1 [290] and deficiency in the FA repair 
pathway [291] have also been implicated in promoting sensitivity to Chk1 depletion, though 
neither of these factors appear to be able to explain the differences between HCT116 and U2OS 
cells. What potentially may be a major factor is that U2OS cells have been shown to undergo 
aberrant mitosis and fail to activate the spindle checkpoint in response to Chk1 inhibition [292], 
making them prone to death by mitotic catastrophe, especially when Chk1 inhibition is combined 
with loss of p53. However, as a tetraploid cell line it may also be susceptible to p53- and p38 
MAPK-dependent cell death after Chk1 depletion [293, 294]. These findings are consistent with our 
observations in paper I that the kinetics and mechanisms of cell death may be dependent on p53 
status in U2OS cells. 
Hypoxia and sensitivity to Chk1 inhibition 
One of the more surprising findings in paper II was the observation that cells were more dependent 
on Chk1 after reoxygenation than during hypoxia, even though it was only during the severe 
hypoxia treatment that the cells activated a replication stress response involving Chk1. In addition, 
the increased sensitivity was also observed following prolonged moderate hypoxia (0.2% O2), 
where there was no activation of any DDR components nor signs of replication stress. Consistent 
with this, a recent publication showed reoxygenated cells to be particularly sensitive to inhibition 
of ATR also after moderate hypoxia [295], not only after severe hypoxia as had been reported 
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previously [224, 251]. Furthermore, the cells displayed increased sensitivity as measured by the 
fraction of γH2AX positive cells at 24 hours also if the Chk1 inhibitors were added at 6 hours after 
reoxygenation (paper II and results not shown), which is long after replication has resumed in the 
reoxygenated cells, indicating that this effect is distinct from the previously reported role of Chk1 in 
reoxygenation-induced replication restart after periods of severe hypoxia [253]. For the clonogenic 
survival assays showing increased sensitivity to Chk1 inhibition after reoxygenation, Chk1 inhibitors 
were also not administered immediately after reoxygenation, but up to 45 minutes later, as the 
cells had to be plated out after removal from the hypoxia chamber. Together, these results indicate 
that the increased dependence of Chk1 after reoxygenation is due to lack of one or more factors 
that are downregulated or inactivated by prolonged hypoxia and which require several hours to 
regain their level or activity, likely involving transcriptional or translational mechanisms. Among the 
factors reported to be downregulated by prolonged hypoxia are the MCM proteins, with 
subsequent reduced loading of replication complexes [221, 296]. Since decreased loading of MCM 
complexes has been implicated in promoting sensitivity to replication stress [151], this may be a 
factor promoting increased sensitivity to Chk1 inhibitors, yet we did not observe decreased loading 
of MCM complexes in our experiments (paper II). None the less, there may be other factors 
involved in replication that are decreased to such an extent by prolonged hypoxia that replication 
fork stalling is increased, as we observed to be the case for reoxygenated cells exposed to Chk1 
inhibitors (paper II). Furthermore, prolonged hypoxia is known to impair several DNA repair 
pathways (reviewed in [225, 228, 297, 298]), and this decreased DNA repair capacity may last for 
hours or even days after reoxygenation, depending on the duration and severity of the hypoxia 
treatment. Since inhibition of Chk1 induces replication stress, it could be that the decreased repair 
capacity of reoxygenated cells is the cause of the elevated sensitivity to Chk1 inhibition, rather than 
the replication stress induced by hypoxia (see next section).  
While transcriptional and translational responses regulating DNA repair pathways and replication 
factors may explain why reoxygenated cells are particularly sensitive to inhibition of Chk1, they do 
not explain why hypoxic cells are not so. In paper III, we observed that prolonged hypoxia led to 
downregulation of several cell cycle regulators and DDR proteins, consistent with previous reports 
(reviewed in [193, 298]). Since the detrimental effects of Chk1 inhibition are primarily due to 
elevated CDK activity mediated by accumulation of Cdc25A [139], the hypoxia-induced 
downregulation of Cdc25A and several cyclins (see introduction and paper III) in combination with 
the accumulation of cells in G1 phase and upregulation of p21 and p27 (paper III and [205]) 
probably limits the deleterious effects of Chk1 inhibition during hypoxia. Even so, decreased CDK 
activity in hypoxic cells is likely not the only explanation, as at least cyclin B levels were decreased 
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for several hours after reoxygenation (paper III), while increased phosphorylation of H2AX in 
response to Chk1 inhibition was observed within 90 minutes in reoxygenated versus normoxic cells 
(paper II). Interestingly, the downregulation of Cdc25A and suppression of replication initiation in 
hypoxic cells was recently reported to be dependent on ATR activity [299]. On the other hand, 
previous studies have implicated miRs and p21 in this process [212, 213], while depletion of ATR 
has been shown to not affect replication arrest in extreme hypoxia, but rather be involved in 
replication restart after such stress [251]. Some of these discrepancies may be due to differences in 
the hypoxia treatments used, as at least the latter study was conducted with oxygen levels so low 
that both initiation and elongation of replication was inhibited due to lack of deoxynucleotides 
caused by inactivation of RNR [221, 251], whereas only replication initiation but not elongation was 
affected by the hypoxia in the study by Martin et al. [299]. Consistent with the findings in this latter 
study, our results also point to the activation of DDR signaling involving ATR and Chk1 in hypoxic 
conditions that do not induce either complete cell cycle arrest or cell death. Rather, the activation 
of this DDR appears to be reversible, and the γH2AX observed in these cells is most likely a marker 
for activated ATR at RPA-coated ssDNA at stalled replication forks, not for DSBs. In the absence of 
other sources of replication stress these cells will likely be able to resume replication following 
reoxygenation, provided the duration of the hypoxia is not so long that replication forks collapse. In 
this regard, the hypoxia-induced downregulation of essential factors involved in HR and 
maintenance of fork stability, including Chk1 itself, may be one of the reasons for such fork collapse 
occurring. Interestingly, ATR-dependent phosphorylation of H2AX has been shown to be induced in 
response to moderate hypoxia and be required for regulation of angiogenesis [255], while other 
recent studies have shown ATR, ATM and DNA-PK to be involved in the regulation of HIF pathways 
[295, 300, 301]. These studies and our own indicate that there is an extensive interplay between 
the DDR and the cellular response to hypoxia, though there are still many unanswered questions 
remaining on this subject.   
Hypoxia, G2 checkpoint signaling and genomic instability 
Considering the effect hypoxia has on DNA repair pathways, cell cycle regulators and activation of 
DDR, it is not surprising that hypoxia promotes genomic instability (reviewed in [225]). In addition, 
hypoxia is known to promote p53-dependent apoptosis (reviewed in [250]), resulting in selection of 
cells that lack this tumor suppressor and thus the DNA damage-induced G1 checkpoint, making 
them particularly dependent on the G2 checkpoint for maintenance of genomic integrity as we 
addressed in paper I. The stringency of the G2 checkpoint depends on the balance between 
negative and positive regulators, and both the levels and activities of many of these are altered by 
prolonged exposure to hypoxia (paper III and references therein). In paper III, we found that while 
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several of the factors promoting G2 checkpoint activation are downregulated by prolonged 
hypoxia, this was also the case for many of the factors that promote mitotic entry, including cyclin 
B and Plk1. Prolonged hypoxia may thus likely alter the balance between negative and positive 
regulators of the G2 checkpoint, and consequently the stringency of this checkpoint. Following 20 
hours incubation at ~0.03% O2 we observed increased G2 checkpoint activation in U2OS cells. 
Although it remains to be tested whether similar effects are found in other cell lines and after 
different hypoxic conditions, these results suggest that prolonged hypoxia causes a more stringent 
G2 checkpoint that counteracts rather than contributes to hypoxia-induced genomic instability.  
The exact role of or mechanism for hypoxia-induced downregulation of these cell cycle regulators is 
not clear, though Plk1 has been implicated in regulation of the mTOR pathway [302], while 
expression of cyclin B1 has been reported to be regulated by eIF4E and is decreased in response to 
mTOR inhibition [303]. Decreased levels of cyclin B are also observed in freeze tolerant wood frogs 
in response to anoxia [304, 305] and is there thought to promote stress tolerance by decreasing 
cell cycle progression. In general, hypoxia mediates cell cycle delay by upregulation of CDK 
inhibitors and downregulation of cyclins, and at least cyclin D1 is known to be a HIF target [210], 
though HIF-independent mechanisms have also been shown to be involved [306]. Based on these 
studies and our own findings, it is not unlikely that the balance of positive versus negative 
regulators of mitotic entry favor a more stringent G2 checkpoint in hypoxic cells. Even so, the 
decreased repair capacity of cells exposed to prolonged hypoxia may also contribute to delayed 
mitotic entry of irradiated cells. While our findings indicate a more stringent G2 checkpoint in 
hypoxic cells mediated by decreased levels of Plk1 and cyclin B in G2 cells, we have not yet 
assessed the stringency of the G2 checkpoint as measured by number of γH2AX foci remaining as 
cells enter mitosis, as was done in a recent study from our research group [281]. However, such 
studies are under way, and will help to determine whether hypoxic cells merely abrogate the G2 
checkpoint with delayed kinetics due to impaired repair capacity or if they enter mitosis with less 
damage than normoxic cells after irradiation.            
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Concluding remarks 
As mentioned in the introduction, cancer is a disease that is both caused by and treated with DNA 
damage. Understanding the molecular basis of cancer therefore requires the understanding of the 
cellular responses to DNA damage, and this knowledge may help us find new potential targets for 
improvement of cancer therapy. Most importantly, we need to find those aspects of the DDR that 
differ between cancer cells and normal tissue to optimize the therapeutic ratio, thus improving 
chance of survival and life quality for the patients.  
In this thesis, two main tumor specific traits and the potential for targeting them by inhibition of 
Chk1 were addressed, namely p53 status and hypoxia. In paper I, we found p53 status to be 
important for radiosensitization by Chk1 inhibition, as previously suggested, though this study also 
showed p53 status to be of lesser importance in mediating response to Chk1 inhibition than other 
traits the cancer cells had acquired during their process towards malignant transformation. In 
paper II, we addressed the potential for targeting hypoxic tumor cells by inhibition of Chk1, and 
found that while enhanced sensitivity to inhibition of Chk1 is not observed in hypoxic cells, 
reoxygenated cells do depend more on this kinase for survival. In addition, this study also showed 
that hypoxic and normoxic cells are radiosensitized to a similar extent by Chk1 inhibition. In paper 
III, we studied the effect of prolonged hypoxia on the Chk1 dependent G2 checkpoint, based on 
observations made during the work on paper II that hypoxia alters the levels of several G2 
checkpoint regulators. We found that activation of the IR-induced G2 checkpoint may be enhanced 
by prolonged hypoxia, which may counteract rather than promote hypoxia-induced genomic 
instability.  
These studies have highlighted some of the aspects regarding the DDR and the cellular responses 
to hypoxia, and the extensive crosstalk existing between these pathways. In order to exploit the full 
potential of Chk1 inhibitors in the clinic, we need to learn more about these processes, both in vitro 
and in vivo, so that we can determine which patients and what type of tumors will respond best to 
such treatments, and avoid giving such agents to non-responders. Detrimental side effects and 
poor pharmacokinetics have been an issue in previous clinical trials with Chk1 inhibitors [174, 180], 
and currently there are only two Chk1 inhibitors in ongoing trials (www.clinicaltrials.gov). 
Hopefully, these and future trials will yield more promising results for the use of Chk1 inhibitors in 
the clinic.     
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